candemox comp 16 mg/12,5 mg tablett
sandoz a/s - hydroklortiazid; kandesartancilexetil - tablett - 16 mg/12,5 mg - kandesartancilexetil 16 mg aktiv substans; laktosmonohydrat hjälpämne; hydroklortiazid 12,5 mg aktiv substans - kandesartan och diuretika
candemox comp 32 mg/12,5 mg tablett
sandoz a/s - hydroklortiazid; kandesartancilexetil - tablett - 32 mg/12,5 mg - kandesartancilexetil 32 mg aktiv substans; hydroklortiazid 12,5 mg aktiv substans; laktosmonohydrat hjälpämne - kandesartan och diuretika
candemox comp 32 mg/25 mg tablett
sandoz a/s - hydroklortiazid; kandesartancilexetil - tablett - 32 mg/25 mg - kandesartancilexetil 32 mg aktiv substans; hydroklortiazid 25 mg aktiv substans; laktosmonohydrat hjälpämne - kandesartan och diuretika
candemox comp 8 mg/12,5 mg tablett
sandoz a/s - hydroklortiazid; kandesartancilexetil - tablett - 8 mg/12,5 mg - kandesartancilexetil 8 mg aktiv substans; laktosmonohydrat hjälpämne; hydroklortiazid 12,5 mg aktiv substans - kandesartan och diuretika
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - grisar - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
adrenalin bradex 1 mg/ml injektionsvätska, lösning
bradex s.a. - adrenalintartrat - injektionsvätska, lösning - 1 mg/ml - adrenalintartrat 1,8 mg aktiv substans; natriummetabisulfit hjälpämne
teicoplanin bradex 200 mg pulver och vätska till injektions-/infusionsvätska, lösning
bradex s.a. - teikoplanin - pulver och vätska till injektions-/infusionsvätska, lösning - 200 mg - teikoplanin 200 mg aktiv substans
teicoplanin bradex 400 mg pulver och vätska till injektions-/infusionsvätska, lösning
bradex s.a. - teikoplanin - pulver och vätska till injektions-/infusionsvätska, lösning - 400 mg - teikoplanin 400 mg aktiv substans
meropenem bradex 500 mg pulver till injektions-/infusionsvätska, lösning
bradex s.a. - meropenemtrihydrat - pulver till injektions-/infusionsvätska, lösning - 500 mg - meropenemtrihydrat 570 mg aktiv substans
meropenem bradex 1 g pulver till injektions-/infusionsvätska, lösning
bradex s.a. - meropenemtrihydrat - pulver till injektions-/infusionsvätska, lösning - 1 g - meropenemtrihydrat 1140 mg aktiv substans